ORIGINAL ARTICLE
Significance of β-catenin expression for the incidence of pathological fractures in giant cell tumors of bone
 
More details
Hide details
 
Submission date: 2016-05-20
 
 
Final revision date: 2016-11-29
 
 
Acceptance date: 2016-11-30
 
 
Publication date: 2017-02-10
 
 
Pol J Pathol 2016;67(4):345-350
 
KEYWORDS
TOPICS
ABSTRACT
Aim of the study is to determine the possible roles of p53, cyclin D1, β-catenin and Ki-67 in the increase in risk of fractures in patients with giant cell tumor of bone.
The study included a total of 164 patients with giant cell tumor of bone (GCTB), 21 (12.8%) with and 143 (87.2%) without fracture. The samples were analyzed immunohistochemically for expression of Ki-67, p53, cyclin D1 and β-catenin.
According to the immunohistochemical expression of p53 and Ki 67 in mononuclear stromal cells, as well as of cyclin D1 in multinuclear giant cells, there was no significant association with immunopositivity and risk of fractures. However, our research revealed that patients with cytoplasmic expression of b-catenin in stromal cells had three times more frequent occurrence of pathological fractures, which was highly statistically significant (χ2 = 7.065; p = 0.008). Moreover, a highly statistically significant correlation between the nuclear expression of β-catenin in giant cells and the incidence of pathological fractures was also found (χ2 = 8.824; p = 0.003).
The study showed that β-catenin expression highly correlates with the incidence of pathological fractures in patients with GCTB. Taking into account that β-catenin is closely linked to activation of the Wnt signaling pathway in GCTB pathogenesis, one could postulate that activation of the Wnt pathway is one of the contributing factors to locally destructive behavior of this tumor, as well as to the incidence of pathological fractures.
REFERENCES (18)
1.
Raskin KA, Schwab JH, Mankin HJ, et al. Giant cell tumor of bone. J Am Acad Orthop Surg 2013; 21: 118-126.
 
2.
Wulling M, Engels C, Jesse N, et al. The nature of giant cell tumor of bone. J Cancer Res Clin Oncol 2001; 127: 467-474.
 
3.
Errani C, Ruggieri P, Asenzio MA, et al. Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev 2010; 36: 1-7.
 
4.
van der Heijden, Dijkstra S, Campanacci D, et al. Giant cell tumor with pathologic fracture: should we curette or resect? Clin Orthop Relat Res 2013; 471: 820-829.
 
5.
Balke M, Schremper L, Gebert C et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 2008; 134: 969-978.
 
6.
Alberghini M, Kliskey K, Krenacs T, et al. Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Arch 2010; 456: 97-103.
 
7.
Dongqi L, Jinlei Z, Yi L at al. Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone. World J Surg Oncol 2016; 14: 114-121.
 
8.
Niu X, Zhang Q, Hao L, et al. Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution. J Bone Joint Surg Am 2012; 94:461-467.
 
9.
Jiang HL, Jiang LM, Han WD. Wnt/-catenin signaling pathway in lung cancer stem cells is a potential target for the development of novel anticancer drugs. J BUON 2015; 20: 1094-1100.
 
10.
Kandel R, Li SQ, Bell R, et al. Cyclin D1 and p21 is elevated in the giant cells of giant cell tumors. J Orthop Res 2006; 24: 428-437.
 
11.
Matsubayashi S, Nakashima M, Kumagai K, et al. Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis. Pathol Res Pract 2009; 205: 626-633.
 
12.
Cowan RW, Singh G. Giant cell tumor of bone: a basic science perspective. Bone 2013; 52: 238-246.
 
13.
de Souza PE, Paim JF, Carvalhais JN, Gomez RS. Immunohistochemical expression of p53, MDM2, Ki-67 and PCNA in central giant cell granuloma and giant cell tumor. J Oral Pathol Med 1999; 28: 54-58.
 
14.
Steensma MR, Tyler WK, Shaber AG, et al. Targeting the giant cell tumor stromal cell: functional characterization and a novel therapeutic strategy. Plos One 2013; 8: e69101.
 
15.
Shuxin C, Chunquan L, Bingli W, et al. Identification of differentially expressed genes and their subpathways in recurrent versus primary bone giant cell tumors. Int J Oncol 2014; 45: 1133-1142.
 
16.
Barham W, Frump A, Sherrill T, et al. Targeting the Wnt pathway in synovial sarcoma models. Cancer Discov 2013; 3: 1286-1301.
 
17.
Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005; 18: 68-74.
 
18.
Haydon RC, Deyrup A, Ishikawa A, et al. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 2002; 102: 338-342.
 
eISSN:2084-9869
ISSN:1233-9687
Journals System - logo
Scroll to top